---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-028602"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2026-07-16T11:00:46+00:00"
generated_at: "2026-07-16T11:05:06.147945+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Insmed reports positive 12-month OLE data for TPIP in PAH; sustained improvement across endpoints

## Summary
- 6MWD improved +55.7m (TPIP continued) and +54.1m (placebo crossed) from baseline at Month 12.
- NT-proBNP reduced ~60% in both groups; WHO Functional Class I/II achieved in ~80% of patients.
- REVEAL Lite 2.0 score improved 2.0 points (TPIP continued) and 1.4 points (placebo crossed); ~65% low-risk.
- TPIP well-tolerated with no new safety signals; most common TEAEs: headache (28.6%), cough (15.4%).
- Phase 3 PALM-PAH trial initiated; topline Phase 2b results previously reported June 2025.

## SEC filing metadata
- accession: 0001140361-26-028602
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2026-07-16T11:00:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/0001140361-26-028602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-028602
- JSON: https://secwatch.observer/filing/0001140361-26-028602.json
- Plain text: https://secwatch.observer/filing/0001140361-26-028602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.